Mirum Pharmaceuticals Inc expected to post a loss of 68 cents a share - Earnings Preview

Mirum Pharmaceuticals

04/08/2026 24:34

Mirum Pharmaceuticals Inc MIRM.OQ MIRM.O is expected to  show a rise in quarterly revenue when it reports  results on August 5 for the period ending June 30 2026
The Foster City California-based  company is expected to report a 30.0% increase in revenue to $166.122 million from $127.79 million a year ago, according to the mean estimate from 11 analysts, based on LSEG data.
​LSEG's mean analyst estimate for Mirum Pharmaceuticals Inc is for a loss of 68 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Mirum Pharmaceuticals Inc is $145.00, about 38.6% above its last closing price of $104.59
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.35
-0.35
-1.08
Missed
-205.7
Dec. 31 2026
0.15
0.04
-0.10
Missed
-335.6
Sep. 30 2025
-0.15
-0.16
0.05
Beat
130.4​
Jun. 30 2025
-0.32
-0.33
-0.12
Beat
63.2
​​Mar. 31 2025
-0.36
-0.33
-0.30
Beat
8.9
Dec. 31 2024
-0.23
-0.24
-0.49
Missed
-103.4​
Sep. 30 2024
-0.45
-0.45
-0.30
Beat
33.2
Jun. 30 2024
-0.47
-0.47
-0.52
Missed
-10.1
This summary was machine generated August 3 at 23:34 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)